News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abattis Receives US and Taiwan Trademark Approvals for Anti-viral Brand Defenzall™


1/16/2013 9:07:43 AM

VANCOUVER, Jan. 16, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has been granted Intl Class 5 Trademark for DefenZall in Taiwan and the USA.

Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are pleased to extend the intellectual property of the company as we grow our brands. This mark will be used to brand our proprietary Anti-Viral Nutraceutical Platform of products which are; DefenZall Daily, DefenZall Immune Support and DefenZall Serious Defense They will be launched through our Canadian distributor Hedley Enterprises, on the Internet and via our Distributor in Hong Kong."

About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and bio-similar compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and Animal Nutrition markets. The company owns the exclusive world wide rights to the Vertical Designs Advanced Automated Growing Technologies for these markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.

ON BEHALF OF THE BOARD

'Mike Withrow'
Michael Withrow, President & CEO

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.


SOURCE Abattis Bioceuticals Corp.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES